Skip to main content

Advertisement

SpringerLink
Log in

Utility of Biomarkers in the Management of Inflammatory Bowel Disease

  • Inflammatory Bowel Disease (G Lichtenstein, Section Editor)
  • Published:
Current Treatment Options in Gastroenterology Aims and scope Submit manuscript

Opinion statement

Inflammatory bowel disease (IBD) is comprised of complex clinical and pathological conditions. It runs a chronic course, and proper management requires constant monitoring of disease activity. Recent evidence suggests that subjective patient scores have a poor correlation with disease activity. Endoscopy remains the gold standard for diagnosing and monitoring disease activity. As healthcare is moving towards less costly and less invasive treatments, the need for biomarkers in the management of IBD is evident. Over the last decade, several biomarkers have been found, which may correct the discrepancy between subjective patient scores and the need for endoscopy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

ANCA:

Antineutrophil cytoplasmic antibodies

p-ANCA:

Perinuclear antineutrophil cytoplasmic antibodies

c-ANCA:

Cytoplasmic antineutrophil cytoplasmic antibodies

ASCA:

Antibodies against Saccharomyces cerevisiae

AUROC:

Area under receiver operating characteristic

BMI:

Body mass index

CI:

Confidence interval

CD:

Crohn’s disease

CDAI:

Crohn’s disease activity index

CRP:

C-reactive protein

ESR:

Erythrocyte sedimentation rate

ESLD:

End-stage liver disease

FCP:

Fecal calprotectin

FL:

Fecal lactoferrin

GI:

Gastrointestinal

IBD:

Inflammatory bowel disease

ICU:

Intensive care unit

IBS:

Irritable bowel syndrome

IQR:

Interquartile range

POCER:

Postoperative Crohn’s Endoscopic Recurrence

UC:

Ulcerative colitis

VOC:

Volatile organic compounds

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Zhang YZ, Li YY. Inflammatory bowel disease: pathogenesis. World J Gastroenterol. 2014;20(1):91–9.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis. 2006;12:S3–9.

    Article  PubMed  Google Scholar 

  3. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmcol Ther. 2001;69:89–95.

    Article  Google Scholar 

  4. Leddin DJ, Paterson WG, DaCosta LR, et al. Indium-111-labeled autologous leukocyte imaging and fecal excretion. Dig Dis Sci. 1987;32:377–87.

    Article  CAS  PubMed  Google Scholar 

  5. Siemons L, Klooster PM, Vonkeman HE, van Riel PLCM, Glas CAW, van de Laar MAFJ. How age and sex affect the erythrocyte sedimentation rate and C-reactive protein in early rheumatoid arthritis. BMC Musculoskelet Disord. 2014;15:1.

    Article  Google Scholar 

  6. Cobb WS, Heniford BT, Sigmon LB, et al. Colonoscopic perforations: incidence, management, and outcomes. Am Surg. 2004;70(9):750–7.

    PubMed  Google Scholar 

  7. Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology. 2011;140:1817–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Arai Y, Arihiro S, Matsuura T, et al. Prostaglandin E—major urinary metabolite as a reliable surrogate marker for mucosal inflammation in ulcerative colitis. Inflamm Bowel Dis. 2014;20(7):1208–16.

    Article  PubMed  Google Scholar 

  9. Sandborn WJ, Landers CJ, Tremaine WJ, et al. Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. Mayo Clin Proc. 1996;71:431–6.

    Article  CAS  PubMed  Google Scholar 

  10. Peyrin-Biroulet L, Standaert-Vitse A, Branche J, et al. IBD serological panels: facts and perspectives. Inflamm Bowel Dis. 2007;13(12):1561–6.

    Article  PubMed  Google Scholar 

  11. Mokrowiecka A, Daniel P, Slomka M, et al. Clinical utility of serological markers in inflammatory bowel disease. Hepato-Gastroenterology. 2009;56(89):162–6.

    PubMed  Google Scholar 

  12. Joossens S, Reinisch W, Vermeire S, et al. The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology. 2002;122:1242–7.

    Article  PubMed  Google Scholar 

  13. Reese GE, Constantinides VA, Simillis C, et al. Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Am J Gastroenterol. 2006;101:2410–22.

    Article  CAS  PubMed  Google Scholar 

  14. Soubieres A, Poullis A. Emerging role of novel biomarkers in the diagnosis of inflammatory bowel disease. World J of Gastrointes Pharm and Therp. 2016;7:41–50.

    Article  Google Scholar 

  15. Darlington GJ, Wilson DR, Lachman LB. Monocyte-conditioned medium, interleukin-1, and tumor necrosis factor stimulate the acute phase response in human hepatoma cells in vitro. J Cell Biol. 1986;103:787–93.

    Article  CAS  PubMed  Google Scholar 

  16. Solem CA, Loftus EV, Tremaine WJ, et al. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:707–12.

    Article  PubMed  Google Scholar 

  17. Carlson CS, Aldred SF, Lee PK, et al. Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels. Am J Hum Genet. 2005;77(1):64–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Florin TH, Paterson EW, Fowler EV, Radford-Smith GL. Clinically active Crohn’s disease in the presence of a low C-reactive protein. Scand J Gastroenterol. 2006;41:306–11.

    Article  CAS  PubMed  Google Scholar 

  19. Cantorna MT, Mahon BD. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp Biol Med. 2004;229:1136–42.

    CAS  Google Scholar 

  20. •• Mouli VP, Ananthakrishnan AN. Review article: vitamin D and inflammatory bowel diseases. Aliment Pharmacol Ther. 2014;39:125–36. This review article very nicely summarizes the role of vitamin D and IBD management. It only provides with current literature behind vitamin D in IBD but also future insights and various study limitations of the available studies in the field of vitamin D and IBD

    Article  CAS  PubMed  Google Scholar 

  21. Ooi JH, Chen J, Cantorna MT. Vitamin D regulation of immune function in the gut: why do T cells have vitamin D receptors? Mol Asp Med. 2012;33:77–82.

    Article  CAS  Google Scholar 

  22. Kongsbak M, Levring TB, Geisler C, Von Essen MR. The vitamin D receptor and T cell function. Front Immunol. 2013;4:148.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Sloka S, Silva C, Wang J, et al. Predominance of Th2 polarization by vitamin D through a STAT6-dependent mechanism. J Neuroinflammation. 2011;8:56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006;311:1770–3.

    Article  CAS  PubMed  Google Scholar 

  25. Liu W, Chen Y, Golan MA, et al. Intestinal epithelial vitamin D receptor signaling inhibits experimental colitis. J Clin Invest. 2013;123:3983–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Xue LN, Xu KQ, Zhang W, et al. Associations between vitamin D receptor polymorphisms and susceptibility to ulcerative colitis and Crohn’s disease: a meta-analysis. Inflamm Bowel Dis. 2013;19:54–60.

    Article  PubMed  Google Scholar 

  27. Ananthakrishnan AN, Khalili H, Higuchi LM, et al. Higher predicted vitamin D status is associated with reduced risk of Crohn’s disease. Gastroenterology. 2012;142:482–9.

    Article  CAS  PubMed  Google Scholar 

  28. Ananthakrishnan AN, Cagan A, Gainer VS, et al. Normalization of plasma 25-hydroxy vitamin D is associated with reduced risk of surgery in Crohn’s disease. Inflamm Bowel Dis. 2013;19:1921–7.

    PubMed  PubMed Central  Google Scholar 

  29. Jørgensen SP, Agnholt J, Glerup H, et al. Clinical trial: vitamin D3 treatment in Crohn’s disease—a randomized double-blind placebo-controlled study. Aliment Pharmacol Ther. 2010;32:377–83.

    Article  PubMed  Google Scholar 

  30. Wright EK, De Cruz P, Gearry R, Day AS, Kamm MA. Fecal biomarkers in the diagnosis and monitoring of Crohn’s disease. Inflamm Bowel Dis. 2014;20:1668–77.

    Article  PubMed  Google Scholar 

  31. Lamb CA, Mansfield JC. Measurement of faecal calprotectin and lactoferrin in inflammatory bowel disease. Frontline Gastroenterol. 2011;2(1):13–8.

    Article  CAS  PubMed  Google Scholar 

  32. von Roon AC, Karamountzos L, Purkayastha S, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol. 2007;102:803–13.

    Article  Google Scholar 

  33. Lin JF, Chen JM, Zuo JH, et al. Meta-analysis: fecal calprotectin for assessment of inflammatory bowel disease activity. Inflamm Bowel Dis. 2014;20:1407–15.

    Article  PubMed  Google Scholar 

  34. Sandborn W, Panes J, Zhang H, Yu D, Niezychowski W, Su C. Tu1109 evaluation of the relationship between fecal calprotectin concentrations and clinical and endoscopic outcome measures in a phase 2 study of tofacitinib, an oral janus kinase inhibitor, in active ulcerative colitis. Gastroenterology. 2013;144(5):S–764.

    Article  Google Scholar 

  35. Iskandar HN, Ciorba MA. Biomarkers in inflammatory bowel disease: current practices and recent advances. Transl Res. 2012;159(4):313–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Konikoff MR, Denson LA. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12(6):524–34.

    Article  PubMed  Google Scholar 

  37. Soubieres A, Poullis A. Emerging biomarkers for the diagnosis and monitoring of inflammatory bowel disease. Inflmma Bow Dis. 2016;8:2016–22.

    Article  Google Scholar 

  38. Boon GJ, Day AS, Mulder CJ, et al. Are faecal markers good indicators of mucosal healing in inflammatory bowel disease? World J Gastroenterol. 2015;21(40):11469–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. •• Menees SB, Powell C, Kurlander J, et al. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol. 2015;110:444–54. This metanalysis highlighted how the currently available biomarkers were not useful in distinguishing IBS from healthy controls. It also showed usefulness of CRP and FCP in distinguishing IBD from IBS patients. Also, it proved the fact that ESR plays very little, if any, clinical role

    Article  CAS  PubMed  Google Scholar 

  40. van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ. 2010;341:c3369.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Henderson P, Anderson NH, Wilson DC. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109:637–45.

    Article  CAS  PubMed  Google Scholar 

  42. Sipponen T, Savilahti E, Kolho KL, et al. Crohn’s disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn’s disease activity index and endoscopic findings. Inflamm Bowel Dis. 2008;14:40–6.

    Article  PubMed  Google Scholar 

  43. Lobaton T, Lopez-Garcia A, Rodriguez-Moranta F, et al. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn’s disease. J Crohns Colitis. 2013;7:e641–51.

    Article  PubMed  Google Scholar 

  44. De Vos M, Dewit O, D’ Haens G, et al. Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis. J Crohn Col. 2012;6:557–62.

    Article  CAS  Google Scholar 

  45. D’Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(12):2218–24.

    Article  PubMed  Google Scholar 

  46. Guardiola J, Lobaton T, Rodriguez-Alonso L, et al. Fecal level of calprotectin identifies histologic inflammation in patients with ulcerative colitis in clinical and endoscopic remission. Clin Gastroenterol Hepatol. 2014;12(11):1865–70.

    Article  CAS  PubMed  Google Scholar 

  47. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflam Bowel Dis. 2013;19:332–41.

    Article  Google Scholar 

  48. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn’s disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2010;105:162–9.

    Article  CAS  PubMed  Google Scholar 

  49. Osterman MT, Aberra FN, Cross R, et al. Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol. 2014;12:1887–U1369.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease. Gut. 2005;54:364–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. De Cruz P, Kamm MA, Hamilton AL, et al. Crohn’s disease management after intestinal resection: a randomized trial. Lancet. 2014;385:1406–17.

    Article  PubMed  Google Scholar 

  52. •• Boschetti G, Laidet M, Moussata D, et al. Levels of fecal calprotectin are associated with the severity of postoperative endoscopic recurrence in asymptomatic patients with Crohn’s disease. Am J Gastroenterol. 2015;110:865–72. A prospective trail which established a role of using FCP to post-op recurrence of Crohn’s disease in patients with ileo-colonic disease

    Article  CAS  PubMed  Google Scholar 

  53. Yang Z, Clark N, Park KT. Effectiveness and cost-effectiveness of measuring fecal calprotectin in diagnosis of inflammatory bowel disease in adults and children. Clin Gastroenterol Hepatol. 2014;12:253–62.

    Article  PubMed  Google Scholar 

  54. Kurada S, Alkhouri N, Fiocchi C, et al. Breath analysis in inflammatory bowel disease. Aliment Pharmacol Ther. 2015;41(4):329–41.

    Article  CAS  PubMed  Google Scholar 

  55. Sand B. Biomarkers of inflammation in inflammatory bowel disease. Gastroenterology. 2015;149:1275–85.

    Article  Google Scholar 

  56. •• Patel N, Alkhouri N, Eng K, et al. Metabolomic analysis of breath volatile organic compounds reveals unique breathprints in children with inflammatory bowel disease: a pilot study. Aliment Pharmacol Ther. 2014;40:498–507. The first study of its kind to analyze human breath utilizing SIFT-MS in a pediatric IBD population. The study identified that children with IBD have unique breathprints

    CAS  PubMed  PubMed Central  Google Scholar 

  57. Arasaradnam RP, Covington J, Nwokolo CU. Editorial: metabolomic analysis of breath volatile organic compounds—a new scent for inflammatory bowel disease. Aliment Pharmacol Ther. 2014;40:732–3.

    Article  CAS  PubMed  Google Scholar 

  58. Dryahina K, Španěl P, Pospíšilová V. Quantification of pentane in exhaled breath, a potential biomarker of bowel disease, using selected ion flow tube mass spectrometry. Rapid Commun Mass Spectrom. 2013;27:1983–92.

    Article  CAS  PubMed  Google Scholar 

  59. Coskun M, Bjerrum JT, Seidelin JB, et al. miR-20b, miR-98, miR-125b-1*, and let-7e* as new potential diagnostic biomarkers in ulcerative colitis. World J Gastroenterol. 2013;19:4289–99.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Meuwis MA, Fillet M, Lutteri L, et al. Proteomics for prediction and characterization of response to infliximab in Crohn’s disease: a pilot study. Clin Biochem. 2008;41:960–7.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Inflammatory Bowel Diseases, Digestive Disease Institute-A31, The Cleveland Clinic Foundation, 9500, Euclid Ave Cleveland, Cleveland, OH, 44195, USA

    Gursimran Kochhar MD FACP & Bret Lashner MD MPH

Authors
  1. Gursimran Kochhar MD FACP
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bret Lashner MD MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bret Lashner MD MPH.

Ethics declarations

Conflict of Interest

Gursimran Kochhar declares that he has no conflict of interest.

Bret Lashner declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Inflammatory Bowel Disease

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kochhar, G., Lashner, B. Utility of Biomarkers in the Management of Inflammatory Bowel Disease. Curr Treat Options Gastro 15, 105–115 (2017). https://doi.org/10.1007/s11938-017-0129-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11938-017-0129-z

Keywords

Search

Navigation